Venlafaxine as single therapy associated with hypertensive encephalopathy

IntroductionHypertensive encephalopathy with the clinicoradiological entity posterior reversible encephalopathy syndrome in the setting of venlafaxine as single therapy has not been reported earlier.Case descriptionA 46-year-old man developed hypertensive encephalopathy associated with venlafaxine as single therapy. Magnetic resonance imaging of the brain, pre and post gadolinium, carried out on day 2, displayed an increased T2 signal in the cortex on both the T2 and FLAIR images throughout the frontal and temporal lobes and in the cerebellum. Venlafaxine therapy was stopped. The patient gradually improved and he became seizure free and the blood pressure successively became normal. A magnetic resonance imaging after six weeks displayed marked regression of the abnormalities. On follow-up after 3 months, his blood pressure had been normal and he had not had any symptoms. The prescribed antiepileptic drug was discontinued as well as antihypertensive treatment. He had not experienced any new symptoms at follow-up after one year.Discussion and evaluationThe patient in this report had hypertensive encephalopathy associated with venlafaxine therapy. The imaging findings are compatible with hypertensive encephalopathy/posterior reversible encephalopathy syndrome. Venlafaxine is a drug used very frequently. Venlafaxine may infrequently induce hypertensive crisis.ConclusionHypertensive encephalopathy may rarely occur in the setting of venlafaxine as single therapy even in low to moderate doses. Patients on venlafaxine should have regular monitoring of blood pressure. Knowledge of the side effects is vital. Venlafaxine must be discontinued if significant hypertension persists.

• Publication year

  2015

• Venue

  SpringerPlus

• Publication date

  2015-02-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1186/s40064-015-0883-0PMID 25763307PMCID 4348355
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evaluation of anti-inflammatory activity, effect on blood pressure & gastric tolerability of antidepressants

  2013cited by this paper
• Comprar Drug Information Handbook, 18th | Leonard L. Lance | 9781591952541 | Lexi-Comp Inc

  2009cited by this paper
• Depression Is Associated With Decreased Blood Pressure, but Antidepressant Use Increases the Risk for Hypertension

  2009cited by this paper
• Hypertensive crisis associated with venlafaxine.

  2003cited by this paper
• VENLAFAXINE INDUCED HYPERTENSION:A CASE REPORT

  2001cited by this paper
• Antidepressants as analgesics: an overview of central and peripheral mechanisms of action.

  2001cited by this paper
• Venlafaxine induced hypertension:a case report.

  2001cited by this paper
• Drug Information Handbook

  1998cited by this paper
• Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients.

  1998cited by this paper
• Placebo‐Controlled Trial of Venlafaxine for the Treatment of Major Depression

  1991cited by this paper
• An ascending single-dose tolerance study of WY-45,030, a bicyclic antidepressant, in healthy men

  1987cited by this paper

• Venlafaxine During Electroconvulsive Therapy Is Associated With the Postictal Administration of Antihypertensive Medication.

  2025cites this paper
• A reverse micelle-mediated dispersive liquid-liquid microextraction coupled to high-performance liquid chromatography for the simultaneous determination of agomelatine and venlafaxine in pharmaceuticals and human plasma.

  2023cites this paper
• Duloxetine, Gabapentin, and the Risk for Acute Myocardial Infarction, Stroke, and Out-of-Hospital Death in Medicare Beneficiaries With Non-Cancer Pain

  2023cites this paper
• Delayed Presentation of Posterior Reversible Encephalopathy Syndrome in the Setting of Serotonin-Norepinephrine Reuptake Inhibitors

  2022cites this paper
• Green synchronous spectrofluorimetric method for the simultaneous determination of agomelatine and venlafaxine in human plasma at part per billion levels

  2022cites this paper
• Vestibular migraine treatment: a comprehensive practical review

  2022cites this paper
• Antidepressant Drugs Effects on Blood Pressure

  2021cites this paper
• Serotonin Syndrome Presenting as a Posterior Reversible Encephalopathy Syndrome

  2020cites this paper
• Blood–Brain Barrier Disruption as a Potential Target for Therapy in Posterior Reversible Encephalopathy Syndrome: Evidence From Multimodal MRI in Rats

  2019cites this paper
• Arginine Vasopressin and Posterior Reversible Encephalopathy Syndrome Pathophysiology: the Missing Link?

  2019cites this paper
• Hydrophobic-hydrophilic cross-linked matrices for controlled release formulation of Highly water-soluble drug venlafaxine: Synthesis and evaluation studies

  2018cites this paper
• Duloxetine-related posterior reversible encephalopathy syndrome

  2016cites this paper
• A case report

  2016cites this paper